RNA Therapeutics Market Growth

RNA therapeutics market growth is anticipated at a CAGR of 68% during the period 2023-2035

 

According to a recently published report by Roots Analysis, highly stable nature and efficient treatment potential at relatively less frequent and low dose administrations is driving the next generation RNA therapeutics and vaccines market growth

RNA Therapeutics and RNA Vaccines Industry Overview

The global RNA Therapeutics Market is anticipated to grow at a CAGR of 68% from 2023-2035, reaching USD 948 million by 2035.

Traditional RNA-based therapies are known to be associated with various stability and delivery-related challenges. This has prompted industry stakeholders to modify such therapies to develop next generation therapies possessing structural stability, expression specificity and non-immunogenic nature along with the ability to target a myriad of therapeutic indications. Moreover, the self-replicating characteristics of such therapies confer prolonged therapeutic effects at relatively low and less frequent doses of administration. In addition, the advancements in the development of novel technologies for the development and delivery of such therapies has escalated the interest of industry stakeholders in developing enhanced and modified RNA-based therapies. Considering the vast potential and ability to circumvent challenges associated with the conventional therapeutic modalities, the next generation RNA therapies domain is anticipated to evolve rapidly to become the next big therapeutic segment in the coming decade.

Browse 145+ figures and 120+ market data tables spread across 170+ slides and detailed Table of Content on “RNA Therapeutics Market and RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/rna-therapeutics-market.html

Market Drivers

Various factors contribute to the market growth of next generation RNA therapeutics and vaccines. The growing prevalence of chronic diseases worldwide is fueling the demand for targeted and effective therapeutic approaches. Additionally, the increasing focus of the healthcare providers towards personalized medicine has led to the development of next generation RNA therapeutics and vaccines, possessing target specificity and self-replicability. Further, the advent of novel technologies for the development and delivery of such modalities is driving the adoption of such therapies. These market drivers collectively shape the evolving landscape of the global next generation RNA therapeutics and vaccines market.

Market Restraints

Despite several drivers, next generation RNA therapeutics and vaccines market is facing certain restraints, primarily from the high cost associated with research and development of safe and effective therapeutics and vaccines. It is worth highlighting that the considerable financial investment required for the research and development process serves as a substantial barrier, specifically for small players, potentially slowing down the pace of next generation RNA therapeutics and vaccines development. Further, the high failure rate of such modalities in their clinical trial studies is another observed trend, that is likely to impede the growth rate of such therapies. This, coupled with the challenges related to the targeted delivery of these modalities are expected to be the growth limiting factors for next generation RNA therapeutics and vaccines.

Growth Factors

Despite the challenges, several growth factors continue to drive the next generation RNA therapeutics and vaccines market forward. One notable factor is the growing demand for efficient and targeted therapies that can be administered at low dose frequency and strengths. Additionally, continuous evolution and innovation in research and development of RNA therapeutics and vaccines is another market driver propelling the growth of the market during the forecast period. Moreover, the growing global burden imposed by chronic diseases has stimulated the interest of stakeholders engaged in this domain. Driven by their clinical potential to specifically target and treat various disease indications, the next generation RNA therapeutics and vaccines have gained significant traction and are anticipated to revolutionize the healthcare and medical sector.

RNA Therapeutics and RNA Vaccines Market Segments

Based on the type of modality, the market is segmented into Vaccines and Therapeutics

• The vaccine segment led the market for RNA therapeutics and vaccines, capturing the revenue share of 93% in 2029.
• The therapeutics segment is anticipated to show the highest growth potential of over 40% annually, during the period 2029-2035.

Based on the type of molecule, the market is segmented into repRNA, sa-mRNA, saRNA and sacRNA

• The sa-mRNA segment led the market for RNA therapeutics and vaccines, capturing the revenue share of 50% in 2029.
• The sacRNA segment is anticipated to show the highest growth potential of over 40% annually, during the period 2029-2035.

Based on the therapeutic area, the market is segmented into Oncological Disorders and Infectious Diseases

• The oncological disorders segment led the market for RNA therapeutics and vaccines, capturing the overall revenue share in 2035.
• The oncological disorders segment is anticipated to show growth potential of over 35% annually, during the period 2029-2035.

Based on the route of administration, the market is segmented into intramuscular, intravenous and intradermal

• The intramuscular segment led the market for RNA therapeutics and vaccines, capturing the revenue share of 93% in 2029.
• The intravenous segment is anticipated to show the highest growth potential of over 40% annually, during the period 2029-2035.

Based on the key geographical regions, the market is segmented into North America and Asia Pacific

• North America dominated the RNA therapeutics and vaccines market and accounted for the largest revenue share of about 99.7% in 2035.
• In Asia-Pacific, the next generation RNA therapeutics and vaccines market is anticipated to show the highest growth potential of over 50% annually, during the period 2032-2035.

Key Companies Profiled

The RNA therapeutics and RNA vaccines market report also includes detailed profiles of key players (listed below) engaged in the development of RNA therapeutics and RNA vaccines:

• Alphavax
• Arcturus Therapeutics
• Gritstone Bio
• HDT Bio
• MiNA Therapeutics
• VLP Therapeutics

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/rna-therapeutics-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com